Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy
Menopausal Review · 2023 · 22 (2) · 117-119
DOI: 10.5114/pm.2023.128815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Menopausal Review, 2023. Verfasst von Jonathan Douxfils und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
AMA Douxfils J, Foidart J, Gaspard U, et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815. APA Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., & Jost, M. et al. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), 117-119. https://doi.org/10.5114/pm.2023.128815 Chicago Douxfils, Jonathan, Jean-Michel Foidart, Ulysse Gaspard, Guillaume Chatel, Mélanie Taziaux, Maud Jost, and Céline Gérard et al. 2023. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy". Menopause Review/Przegląd Menopauzalny 22 (2): 117-119. doi:10.5114/pm.2023.128815. Harvard Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., Jost, M., Gérard, C., and Morimont, L. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), pp.117-119. https://doi.org/10.5114/pm.2023.128815 MLA Douxfils, Jonathan et al. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy." Menopause Review/Przegląd Menopauzalny, vol. 22, no. 2, 2023, pp. 117-119. doi:10.5114/pm.2023.128815. Vancouver Douxfils J, Foidart J, Gaspard U, Chatel G, Taziaux M, Jost M et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815.
Autor:innen und Institutionen
- Department of Pharmacy, Namur Research for Life Sciences, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.
- Department of Gynecology, University of Liège, Liège, Belgium.
- Mithra Pharmaceuticals, Liège, Belgium.
Zitieren
APA
Douxfils, J., Foidart, J. M., Gaspard, U., Chatel, G., Taziaux, M., Jost, M., Gérard, C., & Morimont, L. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopausal Review, 22(2), 117-119. https://doi.org/10.5114/pm.2023.128815
Vancouver
Douxfils J, Foidart JM, Gaspard U, Chatel G, Taziaux M, Jost M, et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy. Menopausal Review. 2023;22(2):117-119. doi:10.5114/pm.2023.128815
BibTeX
@article{Douxfils2023,
author = {Douxfils, Jonathan and Foidart, Jean-Michel and Gaspard, Ulysse and Chatel, Guillaume and Taziaux, Mélanie and Jost, Maud and Gérard, Céline and Morimont, Laure},
title = {Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for the ideal oestrogen therapy},
journal = {Menopausal Review},
year = {2023},
volume = {22},
number = {2},
pages = {117--119},
doi = {10.5114/pm.2023.128815}
}
EUVIMED